Ipidacrine

SKU: orb1299409

Description

Ipidacrine (NIK-247) is a small molecule compound investigated as a potential therapeutic agent for dementia. Its research applications include in vitro studies on cholinesterase inhibition and in vivo models for evaluating cognitive enhancement, primarily within the field of neurodegenerative disease research.

Research Area

Pharmacology & Drug Discovery

Key Properties

• CAS Number: 62732-44-9
• MW: 188.27
• Purity: 99.99% (May vary between batches)
• Formula: C₁₂H₁₆N₂
• SMILES: Nc1c2CCCc2nc2CCCCc12
• Target: Potassium Channel,Others,Sodium Channel,Cholinesterase (ChE)
• Solubility: 10% DMSO+40% PEG300+5% Tween 80+45% Saline:1 mg/mL (5.31 mM);DMSO:10 mg/mL (53.12 mM)

Bioactivity

• In Vivo:
  A single oral administration of ipidacrine (0.3 and 1 mg/kg) reduced the increased total latency induced by scopolamine in this task. The repeated administration of ipidacrine (1 mg/kg) of once a day for 5 successive days reduced the increased total latency induced by scopolamine to the levels of the saline-treated control rats in this task.Ipidacrine was rapidly taken up into the brain within 5 min. Moreover, higher drug levels were observed mainly in the cortex and hippocampus, which both play important roles in learning and memory. Thus, a previous study together with this investigation indicate that ipidacrine improves amnesia which consists of the impairment of the working and reference memory in various animal models, suggesting that ipidacrine is a useful candidate for the therapy of patients with Alzheimer's disease.

Storage & Handling

• Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

Inhibitor, Ipidacrine, inhibit, nootropic, NIK‐247, Cholinesterase (ChE), cholinesterase, Alzheimer disease

Compound Identifiers

PubChem CID

604519